CRVSCorvus Pharmaceuticals, Inc.
$10.52+79% 1Y
$10.52
$6.0452 weeks$25.52
CRVS as reported
- Net income
- −$54M
Net income · +20% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$45M
Free cash flow · +16% year on year · trailing twelve months to Q2 2026
- EPS
- −$0.61
EPS · −38% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$54M | +20% | Q2 2026 |
| EPS | −$0.61 | −38% | Q2 2026 |
| ROE | −22% | n/a | Q2 2026 |
| ROA | −20% | n/a | Q2 2026 |
| Free cash flow | −$45M | +16% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Corvus Pharmaceuticals, Inc. (CRVS) · Net incomeNet incomeCorvus Pharmaceuticals, Inc. (CRVS)
On our screens:Most shorted stocks